Benitec Biopharma (BNTC) Stock Analysis

What Benitec Biopharma does

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Key metrics

ETFs linked to BNTC

Broad-market and Healthcare sector ETFs an investor holding Benitec Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BNTC fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Benitec Biopharma?

Benitec Biopharma trades under the ticker BNTC on NASDAQ.

Which exchange is BNTC listed on?

BNTC is listed on NASDAQ.

What sector does Benitec Biopharma operate in?

Benitec Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BNTC in a portfolio?

PortView shows BNTC's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.